Colorectal Cancer - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036

Colorectal Cancer Market Outlook and Forecast

Thelansis's "Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Colorectal Cancer Overview

Colorectal cancer (CRC) is a malignancy of the colon or rectum shaped by diverse genetic and epigenetic changes. It may cause altered bowel habits, rectal bleeding, abdominal discomfort, anemia, or weight loss, although early disease can be asymptomatic. Treatment depends on tumor site, stage, molecular profile, and patient fitness; localized disease is commonly managed with surgery, with chemotherapy or radiotherapy used as indicated. Advanced disease may require systemic chemotherapy, biologic agents, or immunotherapy. Testing for mismatch-repair/microsatellite-instability status, RAS and BRAF mutations, HER2, and rare gene fusions can guide treatment. Options include checkpoint inhibitors for MSI-H/dMMR tumors, BRAF-directed combinations, and KRAS G12C-targeted therapy for eligible patients. In 2026, U.S. approval expanded to atezolizumab plus chemotherapy after resection of stage III dMMR colon cancer. Resistance and recurrence remain important challenges.

Market Overview

• The Spain colorectal cancer market is projected to grow from $572M in 2026 to $705M by 2036.
• Market growth is driven by:
• Increasing adoption of targeted therapies and immunotherapy in eligible patients
• Advances in precision medicine and biomarker-guided treatment
• Future growth will depend on treatments that improve survival and expand options for patients with advanced disease.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Bristol-Myers Squibb
• Syndax Pharmaceuticals
• Cardiff Oncology
• Lyell Immunopharma, Inc.
• Leap Therapeutics, Inc.
• Exelixis
• Takeda
• AbbVie
• NGM Biopharmaceuticals, Inc.
• Genentech, Inc.
• BeiGene
• Merck Sharp & Dohme LLC
• Redx Pharma Ltd.
• Akeso
• Vividion Therapeutics, Inc.
• NovaOnco Therapeutics Co., Ltd.
• Amgen
• Novartis Pharmaceuticals